Faculty Opinions recommendation of Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.

Author(s):  
Peter R Bernstein
2019 ◽  
Vol 108 (7) ◽  
pp. 2476-2483 ◽  
Author(s):  
Bo Feng ◽  
Mark West ◽  
Nandini C. Patel ◽  
Travis Wager ◽  
Xinjun Hou ◽  
...  

2015 ◽  
Vol 2 (4) ◽  
pp. 69-73
Author(s):  
P Mehrbod ◽  
F Fotouhi ◽  
G Irani Mokhtari ◽  
A Mohammadpour ◽  
B Farahmand ◽  
...  

2005 ◽  
Vol 96 (3) ◽  
pp. 171-177 ◽  
Author(s):  
Dutra JMF ◽  
Bonilha VL ◽  
De Souza W ◽  
Carvalho TMU

1998 ◽  
Vol 143 (10) ◽  
pp. 1893-1909 ◽  
Author(s):  
K. Noma ◽  
K. Kiyotani ◽  
H. Kouchi ◽  
Y. Fujii ◽  
Y. Egi ◽  
...  

2019 ◽  
Vol 9 (o3) ◽  
Author(s):  
Zaid M. Jaber Al-Obaidi ◽  
Omar F. Abdul- Rasheed ◽  
Monther F. Mahdi ◽  
Ayad M.R. M.R. Raauf

Background: Undoubtedly, cancer is regarded as a major concern for researchers alongside the whole humanity for its high mortality rates. At this moment, there must be some researchers working hard to design, synthesize, and biologically investigate the effects of some potential candidates to fight back cancer. Materials and methods: In previous unpublished work, the authors successfully designed, synthesized, characterized a potential two spebrutinib analogues. Consequently, these analogues were evaluated with the employment of MCF-7, HCT116, and MDCK cell lines. Results: In respect to the spebrutinib standard, one of these analogues has superior activity against MCF-7 cell line (IC50; 10.744 µg/mL against 13.566 µg/mL for spebrutinib) and an enhanced toxicity profile on MDCK cell line (IC50; 8.653 mg/mL against 4.011 mg/mL for spebrutinib). Conclusion: The two compounds showed good activity against breast and colon cell lines and enhanced toxicity profile against normal kidney cell line in respect to spebrutinib standard.


2017 ◽  
Vol 106 (9) ◽  
pp. 2909-2913 ◽  
Author(s):  
Maria Karlgren ◽  
Ivailo Simoff ◽  
Maria Backlund ◽  
Christine Wegler ◽  
Markus Keiser ◽  
...  

2020 ◽  
Vol 22 (12) ◽  
pp. 1840-1850 ◽  
Author(s):  
Catherine Hanna ◽  
Kathreena M Kurian ◽  
Karin Williams ◽  
Colin Watts ◽  
Alan Jackson ◽  
...  

Abstract Background The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological side effects of TMZ. The OPARATIC trial was conducted to measure penetration of recurrent glioblastoma by olaparib and assess the safety and tolerability of its combination with TMZ. Methods Preclinical pharmacokinetic studies evaluated olaparib tissue distribution in rats and tumor-bearing mice. Adult patients with recurrent glioblastoma received various doses and schedules of olaparib and low-dose TMZ in a 3 + 3 design. Suitable patients received olaparib prior to neurosurgical resection; olaparib concentrations in plasma, tumor core and tumor margin specimens were measured by mass spectrometry. A dose expansion cohort tested tolerability and efficacy of the recommended phase II dose (RP2D). Radiosensitizing effects of olaparib were measured by clonogenic survival in glioblastoma cell lines. Results Olaparib was a substrate for multidrug resistance protein 1 and showed no brain penetration in rats but was detected in orthotopic glioblastoma xenografts. Clinically, olaparib was detected in 71/71 tumor core specimens (27 patients; median, 496 nM) and 21/21 tumor margin specimens (9 patients; median, 512.3 nM). Olaparib exacerbated TMZ-related hematological toxicity, necessitating intermittent dosing. RP2D was olaparib 150 mg (3 days/week) with TMZ 75 mg/m2 daily for 42 days. Fourteen (36%) of 39 evaluable patients were progression free at 6 months. Olaparib radiosensitized 6 glioblastoma cell lines at clinically relevant concentrations of 100 and 500 nM. Conclusion Olaparib reliably penetrates recurrent glioblastoma at radiosensitizing concentrations, supporting further clinical development and highlighting the need for better preclinical models.


2008 ◽  
Vol 74 (17) ◽  
pp. 5383-5391 ◽  
Author(s):  
Dmitriy V. Volokhov ◽  
Hyesuk Kong ◽  
Joseph George ◽  
Christine Anderson ◽  
Vladimir E. Chizhikov

ABSTRACT In this study, we describe our results on the evaluation of the ability of different permissive mammalian cell lines to support the biological enrichment of mycoplasma species known to be bacterial contaminants of cell substrates. The study showed that this approach is able to significantly improve the efficiency of mycoplasma detection based on nucleic acid testing or biochemical technologies (e.g., MycoAlert mycoplasma detection). Of 10 different cell lines (Vero, MDBK, HEK-293, Hep-G2, CV-1, EBTr, WI-38, R9ab, MDCK, and High Five) used in the study, only MDCK cell culture was found to support the efficient growth of all the tested mycoplasmas (Mycoplasma arginini, M. bovis, M. fermentans, M. gallinaceum, M. gallisepticum, M. synoviae, M. hominis, M. hyorhinis, M. orale, M. salivarium, and Acholeplasma laidlawii) known to be most frequently associated with contamination of cell substrates and cell lines in research laboratories or manufacturing facilities. The infection of MDCK cells with serial dilutions of each mycoplasma species demonstrated that these common cell line contaminants can be detected reliably after 7-day enrichment in MDCK cell culture at contamination levels of 0.05 to 0.25 CFU/ml. The High Five insect cell line was also found to be able to support the efficient growth of most mycoplasma species tested, except for M. hyorhinis strain DBS1050. However, mycoplasma growth in insect cell culture was demonstrated to be temperature dependent, and the most efficient growth was observed when the incubation temperature was increased from 28°C to between 35 and 37°C. We believe that this type of mycoplasma enrichment is one of the most promising approaches for improving the purity and safety testing of cell substrates and other cell-derived biologics and pharmaceuticals.


Sign in / Sign up

Export Citation Format

Share Document